BioSpace

Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected

Troriluzole, in development for spinocerebellar ataxia, was rejected nearly a year ago when the FDA took issue with the design of Biohaven’s registrational study. The agency has now agreed to review a new application and render a decision in the first quarter of 2027.

By BioSpace

1 min read
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights